Microdosing Psilocybin for Depression: What Research Shows

Microdosing psilocybin has gone from niche Silicon Valley practice to mainstream wellness conversation in under a decade. Proponents describe better mood, sharper focus, and reduced anxiety, all without losing their day to a full psychedelic experience. The appeal is obvious.

The problem is that the research has not kept pace with the enthusiasm. The evidence for microdosing specifically is much weaker than the evidence for full-dose psilocybin therapy. That distinction matters, and this post will not smooth it over.

Quick answers

Does microdosing psilocybin work for depression? The best placebo-controlled study found no significant difference between real microdoses and placebo — and expectation was the strongest predictor of who reported improvement.

What is a psilocybin microdose? Typically 0.1–0.3 g of dried P. cubensis, taken on a schedule with regular off-days to prevent tolerance. Sub-perceptual means no visual effects or altered thinking — if you notice those, you’ve exceeded a microdose.

Is microdosing the same as psilocybin therapy? No. Clinical trials use 20–30 mg psilocybin in supervised settings. Microdosing is 1–3 mg taken at home. The research supporting one does not carry over to the other.

Who should not microdose psilocybin? Anyone with a personal or family history of psychosis, schizophrenia, or bipolar I disorder. Also: anyone on lithium (seizure risk), MAOIs (potentiation), or who is in an unstable mental health situation.

What microdosing actually means

A microdose is a sub-perceptual dose: small enough that you experience no visual distortion, no significant perceptual changes, and can function normally at work or in conversation. For dried Psilocybe cubensis, this typically means 0.1–0.3 g. That’s roughly 1–3 mg of psilocybin, compared to the 20–30 mg used in clinical depression studies.

“Sub-perceptual” is the key word. If you’re noticing effects on how things look or feel, you’re not microdosing, you’re just taking a low dose. That’s a real distinction.

Common protocols:

• Fadiman protocol: dose one day, off two days, repeat. The three-day gap is intentional, see below on tolerance.
• Stamets protocol: four days on, three days off.
• As-needed: some people dose only before specific situations (presentations, creative work) rather than on any schedule.

Microdosing’s rise in popularity from roughly 2018 onward was driven almost entirely by anecdotal reports: survey data, Reddit communities, and James Fadiman’s crowd-sourced research project. That’s the evidence base the enthusiasm was built on.

What the research actually shows

Most of the evidence is observational

The bulk of what we know comes from surveys of people who already microdose and report on their experiences. These surveys consistently show positive self-reports: better mood, more focus, reduced anxiety. But self-selected samples of people who chose to microdose and then report on it are not a reliable way to measure a drug’s effects. People who have a bad experience often stop and don’t fill out the survey.

The key placebo-controlled study

The most important study on microdosing is Szigeti et al. 2021, a self-blinded citizen science RCT published in eLife (PMID 33648632). It was the largest placebo-controlled psychedelics trial at the time of publication, with 191 participants completing the full protocol.

Participants sourced their own mushrooms and implemented their own placebo control following online instructions. Both the microdose group and the placebo group reported significant improvements in wellbeing and other psychological measures from baseline. There were no significant between-group differences on most outcomes.

The decisive finding was this: the strongest predictor of reported improvement was not whether someone had taken a microdose. It was what they believed they had taken. When researchers analyzed participants’ guesses about their condition, belief in having taken a microdose explained the outcomes far better than actual drug condition. The study’s conclusion was that the observed benefits were better explained by expectation and placebo effects than by pharmacological action.

This doesn’t mean microdosing does nothing. It means that in this study, with this design, the effect attributable to the drug itself could not be clearly separated from the effect of believing you’d taken it.

One important caveat: participants sourced their own substances, which were not lab-verified. Self-blinding is also imperfect. The trial design was creative and is the best we have for naturalistic microdosing, but it’s not equivalent to a pharmaceutical-grade double-blind RCT.

Contrast with full-dose psilocybin therapy

The evidence for full-dose psilocybin therapy for depression is substantially stronger.

Davis et al. 2021 (PMID 33146667), a Johns Hopkins randomized clinical trial, found that two psilocybin sessions with psychological support produced significantly lower depression scores compared to a delayed-treatment control, with 71% of participants showing clinically significant improvement within one week.

Carhart-Harris et al. 2021 (PMID 33852780) compared psilocybin directly to escitalopram (a standard SSRI) in a phase 2 trial. The primary outcome measure did not show a statistically significant difference between the two, but secondary measures favored psilocybin, including remission rates of 57% vs 28%.

These are real, well-designed trials with meaningful findings. Neither of them says anything about microdosing. They used doses of 20–30 mg psilocybin administered in supervised clinical settings. The mechanism, the experience, and the context are all different from taking 1–2 mg alone at home every three days.

Why microdosing might work (if it does)

There are plausible hypotheses. Psilocybin’s primary action is on 5-HT2A serotonin receptors, and sub-threshold activation of these receptors could theoretically affect default mode network activity, which is implicated in rumination and depression. Some researchers have proposed that even low doses might promote neuroplasticity through BDNF pathways.

These are hypotheses based on mechanism, not confirmed findings in humans at microdose levels. The honest answer is that we don’t know whether microdosing produces meaningful changes in neural function at 1–3 mg, or whether those changes would translate to the clinical outcomes people report.

Practical guidance

If you’re going to microdose despite the uncertain evidence, here’s what the harm reduction picture looks like.

What counts as a microdose for P. cubensis: 0.1–0.3 g dried mushroom. Start at 0.1 g. You can always go up; you can’t un-take a dose.

Potency varies significantly. P. cubensis is the most common species and contains roughly 0.5–1% psilocybin by dry weight. P. azurescens and P. semilanceata (liberty caps) can be 2–3x more potent per gram. If you’re using either of these species, reduce your dose accordingly. Potency also varies between batches of the same species.

Start with one day before committing to a protocol. See how 0.1 g affects you before deciding to dose every three days for a month.

Common mistakes:

• Taking too much: if you notice perceptual effects, you’ve exceeded a microdose. The sub-perceptual threshold is the point.
• Daily use: tolerance to psilocybin builds rapidly. Daily dosing will produce diminishing effects within a few days. This is why the Fadiman protocol includes two off-days, not because the number three is special, but because tolerance needs time to reset.
• Expecting it to replace therapy or medication: even proponents of microdosing don’t claim it substitutes for evidence-based treatment.

Risks and cautions

Legal status: psilocybin is Schedule I in the US federally, meaning possession and distribution are federal crimes. Oregon and Colorado have created regulated therapeutic access frameworks, and several cities have decriminalized personal possession. This is changing, but slowly. Understand your local legal situation before proceeding.

Who should not use psilocybin at any dose: anyone with a personal or family history of psychosis, schizophrenia, or bipolar I disorder. Psilocybin can trigger psychotic episodes in predisposed individuals. This risk applies at microdose levels as well as full doses.

Drug interactions:

• SSRIs and SNRIs: likely to blunt psilocybin effects, including at microdose levels. See our drug interactions guide for more detail.
• Lithium: do not combine with psilocybin at any dose. There are case reports of seizures and cardiac events with this combination. The risk appears to apply across the dose range, not only at high doses.
• MAOIs: significantly potentiate psychedelic effects, making a microdose potentially much stronger than expected.

The honest bottom line

The anecdotal reports on microdosing are numerous and consistently positive. The placebo-controlled evidence is thin, and the most rigorous study we have found that expectation, not pharmacology, may account for most of the reported benefit.

Full-dose psilocybin therapy in supervised clinical settings has strong, growing evidence for treatment-resistant depression. Microdosing does not have equivalent evidence. These are different practices, different doses, and different research questions.

None of this means microdosing is ineffective for every person who tries it. It means that if you’re considering it as a treatment for a mental health condition, you should know that the clinical evidence supporting that use is weak, and it is not a replacement for professional care.

For a broader overview of psilocybin’s effects and risks, see our psilocybin harm reduction guide. For guidance on full psychedelic experiences, see our safe psilocybin trip guide. For comparison with LSD, which has a different but related research landscape for therapeutic use, see our LSD guide.

Sources: PMID 33648632 | PMID 33146667 | PMID 33852780